This chapter explores the advantages of being the first drug manufacturer to market and discusses the differences between Zepbound, Ozepic, and Wigovii in terms of weight loss percentages. It also mentions Eli Lilly's plans to develop a drug that combines three different gut hormones and discusses the potential impact on stock value and expectations of becoming a trillion dollar drug company.
The multi-billion dollar weight-loss drug market has ballooned in the past few years. And the two pharmaceutical companies currently duking it out for market dominance, Novo Nordisk and Eli Lilly, have a century-long rivalry.
Bloomberg News health reporter Madison Muller breaks down how Eli Lilly developed Zepbound, a new drug that can help patients cut more than 20% of their body weight — and why some investors and analysts think it will turn Eli Lilly into the first ever trillion-dollar drug company.
(Corrects characterization of the current size of the weight-loss drug market)
See omnystudio.com/listener for privacy information.